MDMA and the Aging Prostate: An Under-Discussed Precaution?

The High Notes

I wanted to put together this blog post to highlight something that has come up a few times in chatting with men about their experiences, particularly with MDMA, although occasionally it’s been reported to me with other phenethylamine psychedelics as well.

There’s some information out there and it follows from MDMA’s pharmacology that It can make it harder to start urinating. That is documented in young men with healthy prostates. Whereas, if you have an enlarged prostate or Benign Prostatic Hypertrophy (BPH) it could potentially be worse, since the prostate is already narrowing the outlet, making it so there’s less room to absorb this effect.

In the cases I’ve come across, the effect is temporary. It tracks with the drug’s subjective effects which tend to correlate well with blood concentrations, and eases as the drug wears off, usually over four to six hours with a single administration or up to eight hours if a booster is used.

The uncomfortable combination at risk is a full bladder plus a tightened outlet. Standard harm reduction guidance around MDMA use tells you to drink water so you do not become dehydrated, which can exacerbate hyperthermia or risks of adverse effects. That guidance is correct, particularly for hot environments. It also fills a bladder, which may present issues for men with BPH.

This is a precaution, not a reason to rule MDMA out or a black and white kind of contraindication. It belongs in a risk conversation somewhere, not necessarily even at the top of it.

These signs would be concerning and something to watch for: no urine passed in six to eight hours despite the urge, pain low in the abdomen, or a firm belly below the navel. That constellation can signal a medical problem and may not be something to wait out.

If you already struggle to void, have had retention before, or know you carry a large post-void residual, consider talking to a urologist first.

What Have Men Been Telling Me?

Over the past several years a report has come up a handful to times in consultations with men over fifty who have BPH. During MDMA sessions, urination becomes difficult or impossible for hours.

The pattern is consistent among the reports. The urge is present and often intense. The bladder feels full. Nothing comes out, or almost nothing. Discomfort builds across the experience. Two persons described themselves as roughly an hour from driving to an emergency department for catheterization. In both cases, as the drug’s effect faded and they stood in a warm shower with the water running, they were finally able to void and experience relief.

That last detail matters. An outlet blocked by tissue does not open because a man relaxes in warm water. An outlet held shut by smooth muscle tone does. The way these episodes resolve points toward a functional obstruction driven by pharmacology, not a mechanical one by hypertrophy, and toward something that tracks drug levels rather than something structural.

What surprised me is how absent this is from the places people look for information around MDMA. Search harm reduction material, MDMA safety guidance, or patient-facing summaries of MDMA risk and you will find hyperthermia, hyponatremia, serotonin toxicity, cardiovascular strain and bruxism covered thoroughly. It does make sense to focus on these risks, but urinary retention barely appears. The intersection with an aging prostate does not appear at all that I can find.

There is information to support this being a possible issue in the medical literature though. Let’s walk through that information now.

MDMA: A Noradregnergic Drug Acting Upon an Alpha-1 Mediated Outlet

MDMA gets described as a serotonin releasing agent. That may be its primary mechanism as far as creating the subjective effects. It is both accurate and incomplete. In human transporter assays MDMA inhibits norepinephrine uptake more potently than it inhibits dopamine or serotonin uptake (Luethi 2019). That matters because of where norepinephrine acts in the lower urinary tract.

Urination requires two things at once. The detrusor, meaning the muscular wall of the bladder, has to contract. The outlet, meaning the bladder neck and prostatic urethra, has to relax. That outlet is dense with alpha-1A adrenergic receptors. Stimulate them and the outlet tightens. Block them and it opens.

This is not theoretical. It is the entire basis of the most widely prescribed class of BPH medication. Tamsulosin, alfuzosin and silodosin block alpha-1A receptors at the bladder neck and prostatic urethra, lowering outlet resistance so urine can pass. Millions of men take these drugs daily for exactly that reason.

A drug that floods the noradrenergic synapse does the opposite. Functionally, MDMA delivers the reverse of what tamsulosin delivers, at the same receptors, for as long as it is acting.

In a man with a normal prostate the outlet has enough reserve to absorb that. He may notice a little hesitancy and think nothing of it. In a man whose prostate has already narrowed the channel, and whose detrusor has been pushing against elevated resistance for years, the reserve is gone. The same pharmacology that produces a minor annoyance at thirty may produce a real crisis at sixty-five.

None of this is exclusively unique to MDMA. It is a recognized property of the drug class. Urinary retention has been described with alpha-adrenoceptor agonists, and elderly patients carry higher risk because of comorbidities such as BPH or other concurrent medications (Verhamme 2008).

The Duloxetine Parallel

Clinicians who find the MDMA framing unfamiliar may already be familiar with this mechanism with another antidepressant, duloxetine (Cymbalta). Duloxetine is a serotonin-norepinephrine reuptake inhibitor. Augmenting serotonergic and noradrenergic transmission with duloxetine increases bladder capacity and urethral sphincter activity, and that sphincter effect is mediated by alpha-1 adrenergic and serotonergic receptors (Thor & Donatucci 2004). It is why duloxetine was studied for stress urinary incontinence, where raising outlet tone is the therapeutic goal.

Anyone who prescribes SNRIs knows the flip side. Urinary hesitancy is a recognized side effect, and a caution around this effect sits in the labeling (5.13).

MDMA is an acute and far more intense version of that same combination. Serotonergic and noradrenergic, delivered as transporter-mediated release rather than reuptake blockade, over several hours. If you accept that duloxetine can precipitate hesitancy in a man with BPH, the MDMA case asks for no additional leap. Same two neurotransmitter systems, same receptors, same anatomy, larger magnitude.

The Hydration Paradox

A second element could potentially makes this worse, and it comes from safety guidance rather than from the drug.

MDMA harm reduction has emphasized moderate fluid intake for decades, and rightly so. Hyperthermia is the mechanism behind the most severe MDMA fatalities, and in hot, physically active settings adequate hydration is genuinely protective. Nearly every credible harm reduction resource tells you to drink water. Also rightfully so, avoiding overhydration is reasonable since the vasopressin release of MDMA can result in dilutional hyponatremia that can be worsened by excessive water intake.  

For a man who cannot open his outlet, that advice adds volume to a bladder that is not emptying though.

The hydration guidance is not wrong, and nobody should be told to strictly restrict fluids during an MDMA session. However, the two pieces of advice interact, and I have not found that interaction described anywhere. The man following safety instructions most diligently may be the one who ends up in the most discomfort.

One possible harm reduction plan could be deliberate attempts or timed voiding. Emptying early and on a schedule may prevent more severe problems or discomfort later on. This strategy could be weighed against the risks of disrupting the ‘set and setting’ or optimal times for psychological work elicited by the substance.

What Does the Evidence Show?

The case literature is small but unambiguous, and it predates the current wave of MDMA research by decades.

Acute urinary retention after MDMA has been reported since at least 1995 (Bryden 1995), with further cases in the urological (Inman & Greene 2003) and emergency medicine literature. In the most mechanistically explicit of these, the authors note that urinary retention is rarely reported with MDMA or methamphetamine and is thought to result from alpha-adrenoceptor stimulation of the bladder neck (Delgado 2004).

So the mechanism I described above is not my inference. It was proposed by the clinicians who managed these cases. It has simply never been connected to the BPH population.

That connection is the contribution here. The published cases involve young men with structurally normal prostates and full functional reserve, who still retained urine badly enough to present to an emergency department and be catheterized. If MDMA can do that to a twenty-year-old outlet, what should you expect in a sixty-five year old outlet with established obstruction? The same pharmacology, producing symptoms at a lower threshold would be a solid prediction.

One further case deserves mention with the right context. A man with heavy chronic MDMA use developed neurogenic bladder with retention that persisted at one year despite complete cessation. Cystoscopy found no outlet obstruction and he required self-catheterization (Beuerle & Barrueto 2008). That case involved sustained daily use over months, not a therapeutic, ceremonial, or occasional dose, and it should not be read as a likely outcome of episodic use. It does argue against assuming the urinary effects of MDMA are automatically and uniformly transient though.

The absence of this signal elsewhere with other psychedelics is worthy of mention. I found no published reports of urinary retention with psilocybin, LSD or ayahuasca, and nobody has reported that to me either. The classical serotonergic psychedelics do not share MDMA's monoamine-releasing profile, and the silence is consistent with that. This looks like a phenethylamine releaser issue, not a psychedelic issue broadly.

A Caution, Not a Contraindication

I want to be precise about how strong this claim is, because overstating it could be its own kind of harm.

This is not a contraindication. A man over fifty with BPH who uses MDMA is not doing something categorically dangerous the way a man on an MAOI would be. Most men with BPH who use MDMA will notice hesitancy and nothing more.

This is not a controlled finding. No cohort study of urinary function in men with BPH during MDMA sessions exists, and I doubt one is coming soon. What exists is a documented mechanism, a small published case series in men without prostate disease, and a handful of reports with a seemingly consistent pattern from men who have it.

So this is an extrapolation. Established pharmacology at a known receptor target, plus documented cases in a population with full reserve, plus some anecdotal reports in a population without full reserve. That is a reasonable basis for a precaution, yet it is not a basis for a prohibition.

The standard I am applying is the one that applies to informed consent generally. People deserve to understand the whole risk picture, including the predictive parts that never made it onto the standard list, and including the parts where the evidence is suggestive rather than settled, labeled clearly as such.

What To Do With This?

If You Have BPH and You are Considering MDMA

Empty your bladder completely before dosing, then consider going on a schedule afterward. Every two hours, whether or not the urge feels convincing. The signal may be blunted or confusing during the experience. Keep drinking to the usual guidance. Timed voiding seems a better strategy to me than fluid restriction.

Know your own baseline honestly. A man who already takes two minutes to start a stream, who has needed catheterization before, or who carries a known elevated post-void residual sits in a different risk category than a man with mild nocturia. If the former is you, consider talking to a urologist before you use.

Know when to go in. Six to eight hours without voiding despite the urge, pain low in the abdomen, or a palpably distended bladder can signal acute retention. Catheterization treats it simply, and delay risks of bladder injury.

If retention develops, what helps is anything that lowers sympathetic tone. A warm shower, running water, privacy, unhurried time, a setting that is not stimulating. These are not necessarily reliable treatments, but they are reasonable first steps while you decide whether to go in.

If You Are a Clinician

Ask about it. Men do not routinely volunteer urinary symptoms when considering MDMA or other phenethylamine psychedelics, and historically this will not come up unprompted in a harm reduction or preparation/integration consult either.

If you prescribe alpha-blockers for BPH, continuing them through an MDMA session is mechanistically sensible for the outlet. Alpha-1A blockade directly opposes the mechanism described here. Weigh that against the orthostatic and cardiovascular profile of the combination for the individual. In my opinion, the balance is typically going to be skewed towards continuing the BPH treatment.

Watch for additive agents. Anticholinergics for overactive bladder, sedating antihistamines and opioids each independently impair voiding. As mentioned earlier, duloxetine has caused this issue through similar pharmacologic mechanisms, although is also a medication that is very likely to blunt effects of MDMA while raising its blood concentrations and may just be considered contraindicated in combination with MDMA.

If a person has had MDMA-associated retention once, treat the next session as higher risk rather than assuming it was situational or a one off.

What have you experienced? If you have something to report regarding effects of psychedelics upon the ability to urinate I’d be happy to receive your anecdotes at support@spiritpharmacist.com

References

Literature retrieved via PubMed on Oct 15^th 2026.

1. Bryden AA, Rothwell PJ, O'Reilly PH. Urinary retention with misuse of "ecstasy." BMJ. 1995;310(6978):504. doi:10.1136/bmj.310.6978.504a
2. Inman DS, Greene D. The agony and the ecstasy: acute urinary retention after MDMA abuse. BJU Int. 2003;91(1):123. doi:10.1046/j.1464-410x.2003.04018.x
3. Delgado JH, Caruso MJ, Waksman JC, Honigman B, Stillman D. Acute, transient urinary retention from combined ecstasy and methamphetamine use. J Emerg Med. 2004;26(2):173-175. doi:10.1016/j.jemermed.2003.05.007
4. Thor KB, Donatucci C. Central nervous system control of the lower urinary tract: new pharmacological approaches to stress urinary incontinence in women. J Urol. 2004;172(1):27-33. doi:10.1097/01.ju.0000118381.04432.22
5. Verhamme KMC, Sturkenboom MCJM, Stricker BHCh, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 2008;31(5):373-388. doi:10.2165/00002018-200831050-00002
6. Beuerle JR, Barrueto F. Neurogenic bladder and chronic urinary retention associated with MDMA abuse. J Med Toxicol. 2008;4(2):106-108. doi:10.1007/BF03160964
7. Simmler LD, Hysek CM, Liechti ME. Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab. 2011;96(9):2844-2850. doi:10.1210/jc.2011-1143
8. Matsumoto-Miyai K, Yoshizumi M, Kawatani M. Regulatory effects of 5-hydroxytryptamine receptors on voiding function. Adv Ther. 2015;32 Suppl 1:3-15. doi:10.1007/s12325-015-0240-2
9. Luethi D, Kolaczynska KE, Walter M, et al. Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems. J Psychopharmacol. 2019;33(7):831-841. doi:10.1177/0269881119844185

This article is informational. It is not medical advice, not a clearance, and not a recommendation to use any substance. It is recommended you follow the law.